Nona Biosciences and Valink Therapeutics have formed a biologics discovery alliance. The collaboration, branded "Biology to Bispecific" (B2B), unites both companies' complementary platforms and expertise to accelerate the creation of innovative bispecific antibodies and bispecific ADCs.

Under the terms of the agreement, Nona and Valink will combine Nona's industry-leading Harbour Mice fully human antibodies, including its Heavy Chain-only Antibodies (HCAbs), with Valink's LiliumX discovery platform to generate and screen thousands of novel drug candidates. With an initial focus on bsADCs in solid tumours, the collaboration will expand Valink's internal therapeutic pipeline and contribute to future co-development and licensing opportunities.

Previously, Nona Biosciences has supported over 300 drug discovery programmes across multiple therapeutic areas, establishing itself as a leader in biotherapeutics innovation. Now, its extensive antibody repertoire provides a rich library of building blocks for complex biologics.

Dr Di Hong, Chief Executive Officer, Nona Biosciences, commented, "We are excited to collaborate with Valink to accelerate the creation of innovative biotherapeutics. By uniting our industry-leading antibody technology platforms and extensive experiences with Valink's LiliumX discovery engine, we aim to accelerate the pace of bispecific antibody and bsADC discovery and development, ultimately delivering transformative therapies to patients in oncology and beyond."

Valink's LiliumX technology enables high-throughput generation and functional screening of complex drug candidates from antibody fragments. Further empowered by Nona's diverse antibody repertoire, LiliumX is uniquely positioned to drive deep exploration of complex biologics, unveiling unexpected targeting strategies and novel target-pair synergies—hallmarks of Valink's V-gate approach.

Dr Arne Scheu, Chief Executive Officer, Valink Therapeutics, stated, "We are thrilled to form this discovery alliance with Nona – it constitutes a logical and natural expansion of our discovery platform. With Nona, we have found an excellent partner, supercharging our ability to build transformative drugs with which we can meaningfully impact patients' lives."